Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) Patents (Class 424/190.1)
-
Publication number: 20130129740Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: ApplicationFiled: August 30, 2012Publication date: May 23, 2013Applicants: J. Craig Venter Institute, Novartis Vaccines and Diagnostics, Inc.Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Hervé Tettelin, Claire Fraser
-
Publication number: 20130129764Abstract: The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm (Dirofilaria immitis), Ehrlichia Canis, Anaplasma phagocytophilum, and Borrelia burgdorferi. More particularly, this invention relates to antibodies that bind to a heartworm antigen, the E. Canis gp36 polypeptide, the A. phagocytophilum p44 polypeptide, the B. burgdorferi OspA, OspC, OspF, p39, p41 and VlsE polypeptides, and uses thereof.Type: ApplicationFiled: November 2, 2012Publication date: May 23, 2013Applicant: VCA Antech, Inc.Inventor: VCA Antech, Inc.
-
Publication number: 20130129765Abstract: This invention provides a method for stimulating in an individual an immune response against M. catarrhalis. The method comprises administering to an individual a composition comprising M. catarrhalis OppA protein in an amount effective to stimulate an immune response against M. catarrhalis in the individual.Type: ApplicationFiled: April 29, 2011Publication date: May 23, 2013Inventors: Timothy F. Murphy, Min Yang
-
Patent number: 8445001Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: GrantFiled: August 3, 2012Date of Patent: May 21, 2013Assignee: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing, Alexander Von Gabain
-
Patent number: 8445000Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compostions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compostions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.Type: GrantFiled: October 19, 2005Date of Patent: May 21, 2013Assignee: Wyeth LLCInventors: Bret Richard Sellman, Steven Morris Baker
-
Patent number: 8445650Abstract: Modified polypeptides based on the botulinum neurotoxin A heavy chain containing the double mutation Trp-Tyr->Leu-Ser in the ganglioside binding motif Ser-X-Trp-Tyr do not bind polysialogangliosides and nerve endings. The polypeptides are useful in the preparation of nontoxic vaccines against the effects of C. botulinum infection. The modified polypeptides are also useful as vehicles for the transepithelial delivery of diagnostic and therapeutic entities, through formation of conjugates between the polypeptides and the diagnostic or therapeutic entities.Type: GrantFiled: September 25, 2008Date of Patent: May 21, 2013Assignee: Thomas Jefferson UniversityInventors: Lance L. Simpson, Mohammed Elias
-
Publication number: 20130122034Abstract: The novel protein SA1789 from Staphylococcus aureus is provided as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Also provided is a composition, particularly a S. aureus vaccine, comprising SA1789 protein or a fragment or derivative thereof capable of generating an immune response that leads to the killing and clearance of S. aureus.Type: ApplicationFiled: July 8, 2011Publication date: May 16, 2013Inventors: Tessie B. McNeely, Hongxia Fan, Mark Andrew Miller
-
Publication number: 20130122033Abstract: A engineered bacteriophage is herein described, displaying at its surface multiple copies of a polypeptide, which comprises a domain of the bacterial adhesion protein FimH fused with the coat protein pVIII. The domain is preferably the region 45-159aa of the mature protein FimH. The polypeptide beingantigenic, raises a desired immunological response, in particular against urinary tract infections (UTI) in a human or animal. The engineered bacteriophage is therefore suitable for the preparation of vaccinesfor therapy, diagnosis and/or prevention of urinary tract infections (UTI) in a human or animal.Type: ApplicationFiled: June 28, 2011Publication date: May 16, 2013Inventors: Rita De Santis, Olga Minenkova
-
DOSAGE FORM, AND METHODS OF MAKING AND USING THE SAME, TO PRODUCE IMMUNIZATION IN ANIMALS AND HUMANS
Publication number: 20130122106Abstract: An embodiment of the present invention features a dosage form for administering antigen to cause an immune response in an animal or human subject in the nature of a vaccine. The dosage form comprises spheres having an effective amount of antigen to create an immune response and having an average diameter of 0.01 to 10.0 microns. The spheres comprise a polymer selected from the group consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric anhydride) and poly(sebacic anhydride) and derivatives thereof. The spheres can be lyophilized and stored as a powder prior to use. The spheres can then be reconstituted and formulated in buffers with adjuvants.Type: ApplicationFiled: October 19, 2012Publication date: May 16, 2013Applicant: Aphios CorporationInventor: Aphios Corporation -
Patent number: 8440206Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of tuberculosis are also disclosed.Type: GrantFiled: December 20, 2011Date of Patent: May 14, 2013Assignees: Oregon Health & Science University, The United States of America, as represented by the Department of Veteran AffairsInventors: David Lewinsohn, Deborah Lewinsohn
-
Patent number: 8440205Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: March 3, 2005Date of Patent: May 14, 2013Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 8440208Abstract: The present invention provides Chlamydia proteins and methods of use in diagnostic and detection assays as well as in treatment and immunization protocols.Type: GrantFiled: May 1, 2008Date of Patent: May 14, 2013Assignee: Board of Regents, The University of Texas SystemInventor: Guangming Zhong
-
Publication number: 20130115237Abstract: The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a Bacillus anthracis lethal factor (LF) polypeptide, such as a LFn polypeptide. In some embodiments, the LF polypeptide can be fused or otherwise associated with the HIV polypeptide. Other aspect of the present invention relate to use of vaccine comprising a HIV polypeptide and a Bacillus anthracis lethal factor (LF) polypeptide in methods to enhance efficacy traditional antiretroviral therapy.Type: ApplicationFiled: June 9, 2011Publication date: May 9, 2013Applicant: VACCINE TECHNOLOGIES, INCORPORATEDInventors: Yichen Lu, Huyen Cao
-
Publication number: 20130115209Abstract: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2412 polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an antibody that specifically binds to an SA2412 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens including, but not limited to, IsdB. Compositions used to practice the methods of the invention are also encompassed.Type: ApplicationFiled: July 11, 2011Publication date: May 9, 2013Inventors: Tessie B. McNeely, Sharon B. Smith, Julie K. Zorman
-
Publication number: 20130115238Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.Type: ApplicationFiled: January 8, 2013Publication date: May 9, 2013Applicant: NOVARTIS AGInventor: Novartis AG
-
Patent number: 8435537Abstract: Expression system of peptides on the bacterial surface characterized in that membrane-binding region the conserved sequence of the MSP1a protein of Anaplasma marginale.Type: GrantFiled: April 16, 2009Date of Patent: May 7, 2013Assignees: Consejo Superior de Investigaciones Científicas, Universidad de Castilla la ManchaInventors: José De La Fuenta García, Mario Manuel Canales García-Menocal
-
Publication number: 20130108659Abstract: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein the proteins are selected from a defined group of proteins associated with age-dependent immunological responses.Type: ApplicationFiled: January 4, 2013Publication date: May 2, 2013Applicant: Ben-Gurion University of the Negev Research and Development AuthorityInventor: Ben-Gurion University of the Negev Research and Development Authority
-
Patent number: 8431135Abstract: The present disclosure relates to proteins derived from OspC from bacteria of the genus Borrelia, in particular a protein which comprises a first OspC polypeptide, wherein the first OspC polypeptide is linked to a second OspC polypeptide via a disulphide bridge. The disclosure also relates to a method for the detection of antibodies against OspC and a method for the detection of a Borrelia infection, wherein a protein according to the disclosure is employed, and also to a diagnostic kit and a vaccine against Borrelia.Type: GrantFiled: March 22, 2012Date of Patent: April 30, 2013Assignee: Euroimmun Medizinische Labordiagnostika AGInventors: Lars Komorowski, Christian Probst, Anthonina Janssen, Winfried Stöcker
-
Patent number: 8431134Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: GrantFiled: July 31, 2009Date of Patent: April 30, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Gowrisankar Rajam, Sandra Steiner, George M. Carlone, Nikkoj Melnick, Jacquelyn S. Sampson, Joseph E. Martinez, Julie M. Skinner
-
Publication number: 20130101614Abstract: Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.Type: ApplicationFiled: June 15, 2011Publication date: April 25, 2013Applicant: The Regents of the University of CaliforniaInventors: Marcus A. Horwitz, Qingmei Jia
-
Publication number: 20130101613Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.Type: ApplicationFiled: November 26, 2012Publication date: April 25, 2013Applicant: Intercell AGInventor: Intercell AG
-
Publication number: 20130101615Abstract: This invention is a method for immunizing, preventing or treating a Mycobacterium avium subspecies paratuberculosis-associated disease or condition by screening subjects for markers indicative of predisposition or susceptibility to a Mycobacterium avium subspecies paratuberculosis-associated disease or condition and administering a Mycobacterium avium subspecies paratuberculosis vaccine or prophylactic or therapeutic agent.Type: ApplicationFiled: December 14, 2012Publication date: April 25, 2013Inventor: Robert J. Greenstein
-
Publication number: 20130095132Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: September 20, 2012Publication date: April 18, 2013Applicant: STATENS SERUM INSTITUTInventor: STATENS SERUM INSTITUT
-
Publication number: 20130095131Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.Type: ApplicationFiled: September 21, 2012Publication date: April 18, 2013Applicant: Forsyth Dental Infirmary for ChildrenInventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
-
Publication number: 20130084304Abstract: Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.Type: ApplicationFiled: June 9, 2011Publication date: April 4, 2013Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: Billy Hargis, Neil R. Pumford, Young Min Kwon, Sherryll Layton
-
Publication number: 20130078254Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: September 12, 2012Publication date: March 28, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Publication number: 20130078271Abstract: The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.Type: ApplicationFiled: September 13, 2012Publication date: March 28, 2013Applicant: Sanofi Pasteur Limited/Sanofi Pasteur LimiteeInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Patent number: 8404252Abstract: The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis. The present invention provides pharmaceutical compositions of such antigens and/or vaccines. The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection.Type: GrantFiled: July 11, 2008Date of Patent: March 26, 2013Assignee: Fraunhofer USA, Inc.Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuk
-
Patent number: 8404245Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. Equi and subsp. Zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. Zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.Type: GrantFiled: October 10, 2003Date of Patent: March 26, 2013Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Karin Jacobsson, Kenneth Janzon, Lars Frykberg, Margareta Flock, Rune Bergman
-
Publication number: 20130071422Abstract: An immunogenic composition comprises (i) an immuno stimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex, and (ii) a meningococcal serogroup B antigen. In most embodiments, the composition does not include an aluminium salt and does not include an oil-in-water emulsion.Type: ApplicationFiled: March 18, 2011Publication date: March 21, 2013Inventors: Michele Pallaoro, Derek O'Hagan, Rino Rappuoli
-
Publication number: 20130071423Abstract: The invention relates to the use of a combination of SP1298 and SP2205 proteins or functional fragments thereof or homologous proteins or protein fragments thereof of S. pneumoniae for preventing or treating a S. pneumoniae infection, their use for the preparation of a vaccine for the preventive treatment of a S. pneumoniae infection, compositions comprising said proteins of S. pneumoniae or functional fragments thereof, vaccines comprising said proteins or functional fragment thereof, and to a method for in vivo immune protection.Type: ApplicationFiled: February 23, 2010Publication date: March 21, 2013Applicant: STICHTING KATHOLIEKE UNIVERSITEITInventor: Peter Wilhelmus Maria Hermans
-
Publication number: 20130071420Abstract: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed.Type: ApplicationFiled: July 12, 2012Publication date: March 21, 2013Applicant: GLOBEIMMUNE, INC.Inventors: Alex Franzusoff, Donald Bellgrau
-
Patent number: 8398992Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.Type: GrantFiled: December 22, 2011Date of Patent: March 19, 2013Assignee: Polytopos LLCInventors: Michael W Deem, Jeong-Man Park, Hao Zhou
-
Publication number: 20130064846Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: Novartis AGInventors: Vincenzo SCARLATO, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Publication number: 20130064845Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.Type: ApplicationFiled: March 17, 2011Publication date: March 14, 2013Inventors: Francois Malouin, Marianne Allard, Christian Lebeau Jacob, Brian Geoffrey Talbot, Daniel Scholl, Pierre Lacasse, Moussa S. Diarra, Celine Ster
-
Patent number: 8394387Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: GrantFiled: July 31, 2007Date of Patent: March 12, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Patent number: 8394390Abstract: This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.Type: GrantFiled: February 24, 2012Date of Patent: March 12, 2013Assignee: Novartis AGInventors: Cesira Galeotti, Guido Grandi, Vega Masignani, Mariarosa Mora, Mariagrazia Pizza, Rino Rappuoli, Guilio Ratti, Vincenzo Scarlato, Maria Scarselli
-
Publication number: 20130058967Abstract: The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.Type: ApplicationFiled: July 31, 2007Publication date: March 7, 2013Inventors: Stephen H. Leppla, Mary Jo Rosovitz, John B. Robbins, Rachel Schneerson, S. Dana Hsu, Joseph Shiloach, Delia M. Ramirez
-
Patent number: 8389678Abstract: Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum. Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.Type: GrantFiled: March 13, 2012Date of Patent: March 5, 2013Assignee: Medical Diagnostic Laboratories, LLCInventors: John G. Hoey, Denise P. Dimitrov, Lisa B. Huang, Martin E. Adelson, Eli Mordechai
-
Patent number: 8383126Abstract: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described.Type: GrantFiled: October 29, 2007Date of Patent: February 26, 2013Assignee: University of Wales, AberstwythInventors: Galina V. Mukamolova, Arseny S. Kaprelyants, Danielle I. Young, Douglas B. Kell, Michael Young
-
Patent number: 8377446Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: GrantFiled: December 16, 2011Date of Patent: February 19, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Marco Soriani, Isabella Santi
-
Patent number: 8372410Abstract: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.Type: GrantFiled: July 3, 2012Date of Patent: February 12, 2013Assignee: Intercell AGInventors: Andreas Meinke, Min Bui Duc, Eszter Nagy
-
Patent number: 8372393Abstract: Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunologic CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal.Type: GrantFiled: May 3, 2006Date of Patent: February 12, 2013Assignee: Mannkind CorporationInventors: Thomas M. Kündig, John J. L. Simard
-
Patent number: 8372411Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating such antigens and specific uses thereof.Type: GrantFiled: December 14, 2009Date of Patent: February 12, 2013Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Shailesh Dewasthaly, Ulrike Stierschneider
-
Publication number: 20130034577Abstract: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an antigen to produce an immune response may be employed in vaccination or antibody preparation techniques.Type: ApplicationFiled: September 26, 2012Publication date: February 7, 2013Applicant: AUBURN UNIVERSITYInventor: Auburn University
-
Publication number: 20130034560Abstract: The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in Treponema spp. isolated from digital dermatitis in cattle. The present invention further relates to antibodies raised against said proteins or fragments thereof, and the use of said proteins in diagnostic methods in which antibodies are detected as a sign of digital dermatitis in cattle.Type: ApplicationFiled: January 28, 2011Publication date: February 7, 2013Inventors: Anna Rosander, Märit Pringle
-
Patent number: 8367070Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: October 31, 2007Date of Patent: February 5, 2013Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20130028927Abstract: Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis.Type: ApplicationFiled: April 12, 2011Publication date: January 31, 2013Inventors: Thomas Kozel, David Aucoin
-
Publication number: 20130028926Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.Type: ApplicationFiled: November 16, 2010Publication date: January 31, 2013Applicant: GLYCOVAXYN AGInventors: Michael Wacker, Charles Waechter
-
Publication number: 20130022634Abstract: The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically, the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1-subunit of the cholera toxin (CTA1), a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit, the amino acids corresponding to the amino acid 7, arginine, and amino acid 187, cysteine, in the native CTA1 have been replaced.Type: ApplicationFiled: October 28, 2011Publication date: January 24, 2013Applicant: TOLERANZIA ABInventor: Nils Lycke